title: Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
abstract: The activities of hydroxyurea (HU), 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) and cyclophosphamide (CY) were examined in the brown Norway rat myelocytic leukemia model in experiments designed to determine the synergy, optimal drug sequencing, and therapeutic index of combinations of these agents. A single dose of CY or four consecutive daily doses of AMSA produced increased survival in leukemic rats, with a positive-slope dose-response curve up to the maximum tolerated dose (MTD). HU at 1/2 MTD produced a minimal antileukemic effect but significantly potentiated the antineoplastic activity of 1/2 MTD of CY or AMSA with no significant toxic death rate. Drug-sequence experiments demonstrated that maximal synergy was achieved when HU was given immediately after CY but immediately before or during AMSA administration. No significant cure rate was seen with any CY/HU or HU/AMSA sequence. The three drugs given in the sequence of CY followed 3 days later by HU and AMSA simultaneously, however, was curative in the majority of rats with advanced leukemia, whereas other sequences were more toxic or less effective. Each of the drugs in these experiments was given at 1/2 of its single-agent MTD. HU significantly potentiates the antineoplastic effect of CY and AMSA in a drug-sequence-dependent manner in this model, apparently with an improved therapeutic index.
authors.affiliation: University of Nebraska Medical Center, Department of Internal Medicine, Omaha 68105.
authors.forename: W P
authors.initials: WP
authors.lastname: Vaughan
authors.forename: C
authors.initials: C
authors.lastname: Holm
authors.forename: K
authors.initials: K
authors.lastname: Cordel
mesh_terms: D000677:Amsacrine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006918:Hydroxyurea / Q000008:administration & dosage / Q000494:pharmacology*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D051381:Rats; D011914:Rats, Inbred BN
chemical_list: D000677:Amsacrine; D003520:Cyclophosphamide; D006918:Hydroxyurea